Welcome to our dedicated page for Quipt Home Medical news (Ticker: QIPT), a resource for investors and traders seeking the latest updates and insights on Quipt Home Medical stock.
Quipt Home Medical Corp. (QIPT) generates a steady flow of news as a U.S.-based home medical equipment provider focused on end-to-end respiratory care and in-home chronic disease management. Company press releases regularly discuss its role in providing in-home monitoring and disease management services for patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions in the United States healthcare market.
News coverage for QIPT commonly includes financial results and operational updates. For example, Quipt issues quarterly and annual earnings releases that highlight revenue trends, recurring revenue from equipment rentals and respiratory resupplies, Adjusted EBITDA, and operational metrics such as the number of unique patients served and set-ups or deliveries completed. These releases often include management commentary on business performance, revenue stabilization, and the contribution of acquisitions and partnerships.
Another major category of Quipt news involves strategic transactions. The company has announced acquisitions of durable medical equipment providers and a joint venture interest in Hart Medical Equipment, as well as a preferred provider agreement with Ballad Health. These items describe how Quipt works with health systems and hospitals to integrate home medical equipment and respiratory care into hospital discharge processes and post-acute care coordination.
More recently, Quipt’s news has featured corporate and M&A developments, including activist shareholder commentary and, most notably, the December 2025 announcement of a definitive Arrangement Agreement under which a special purpose acquisition vehicle funded by affiliates of Kingswood Capital Management and Forager Capital Management will acquire all outstanding Quipt shares for cash. This transaction, if completed, is expected to result in Quipt becoming a privately held company and its shares being delisted from The Nasdaq Capital Market and the Toronto Stock Exchange.
Investors and observers using this QIPT news page on Stock Titan can review these earnings announcements, acquisition and joint venture updates, health system partnership news, and transaction-related disclosures in one place, helping them understand how Quipt’s home medical equipment and respiratory care strategy is reflected in its public communications.
Quipt Home Medical (NASDAQ: QIPT) reported Q1 2025 financial results with revenue of $61.4 million, down 2% from Q1 2024's $62.6 million. The company faced challenges including the discontinuation of Medicare 75/25 blended rate, withdrawal of Medicare Advantage members, and non-renewal of a disposable supply contract, with a cumulative annual impact of approximately $8.0 million.
Key metrics include: net loss improvement to ($1.1) million or ($0.03) per share, operating cash flow of $9.3 million, and Adjusted EBITDA of $14.0 million (22.8% of revenue). The company maintains strong recurring revenue at 77% of total revenue and serves approximately 157,000 unique patients, a 1% year-over-year increase.
The company completed 221,000 unique set-ups/deliveries in Q1 2025, up 3% from Q1 2024, with 124,000 respiratory resupply set-ups/deliveries. Quipt operates across 140+ locations with approximately 36,000 referring physicians.
Quipt Home Medical Corp. (NASDAQ: QIPT) (TSX: QIPT), a U.S. based home medical equipment provider specializing in respiratory care, has received a proxy solicitation notice from Philotimo Fund, LP, affiliated with Kanen Wealth Management, (KWM). The notice indicates KWM's intention to nominate four director candidates to Quipt's Board of Directors in opposition to the company's candidates.
The company's Board and Nominating and Corporate Governance Committee will review KWM's notice for compliance with company Articles and applicable laws. Lead Independent Director Mark Greenberg emphasized the company's commitment to executing their strategic growth plan and maintaining high corporate governance standards. The company states it has delivered consistent performance despite challenging industry conditions.
Quipt notes that it has not received a timely, valid, and compliant director nomination notice under U.S. securities laws and company Articles. No immediate shareholder action is required.
Quipt Home Medical Corp. (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider specializing in end-to-end respiratory care, has scheduled the release of its fiscal first quarter 2025 financial results for Monday, February 10, 2025, after market close.
The company will hold a conference call for investors on Tuesday, February 11, 2025, at 10:00 a.m. (ET), hosted by CEO Gregory Crawford and CFO Hardik Mehta. Participants can join via Canada/US Toll Free at 1 (844) 763 8274 or International at 1 (647) 484 8814. A live webcast will be available through the investor section of Quipt's website.
Quipt Home Medical (NASDAQ: QIPT) reported its fiscal year 2024 financial results, posting revenue of $245.9 million, a 16.2% increase from 2023's $211.7 million. The company achieved organic growth of $7.1 million (3%) and maintained strong recurring revenue at 78% of total revenue. Adjusted EBITDA reached $57.9 million (23.5% margin) compared to $50.6 million in 2023.
Q4 2024 revenue was $61.3 million, up 3% from Q4 2023, with sequential organic growth of 1%. The company faced challenges including a Medicare 75/25 relief pause and a cyberattack on Change Healthcare, impacting revenue by approximately $5 million and $3 million respectively. The customer base grew 4% year-over-year to 153,000 unique patients, with completed set-ups/deliveries increasing 13% to 854,000.
Quipt Home Medical Corp. (NASDAQ: QIPT) (TSX: QIPT), a U.S. based home medical equipment provider specializing in end-to-end respiratory care, has scheduled the announcement of its fiscal fourth quarter and full year 2024 financial results for December 16, 2024, after market close. The company will host a conference call for investors on December 17, 2024, at 10:00 a.m. ET, led by CEO Gregory Crawford and CFO Hardik Mehta. The call will be accessible via toll-free numbers for Canada/US participants and international callers, with a live webcast available through the company's investor relations website.
Quipt Home Medical Corp. (NASDAQ: QIPT; TSX: QIPT) reported its Q3 fiscal 2024 financial results. Key highlights include:
- Revenue increased 6.1% year-over-year to $64.0 million
- Organic growth contributed 3% year-over-year
- Adjusted EBITDA rose 2.7% to $14.2 million, representing 22.3% of revenues
- Net loss was $(1.7) million, or $(0.04) per diluted share
- Cash flow from operations for the nine months ended June 30, 2024, was $28.6 million
- The company served 270,087 unique patients in the nine months ended June 30, 2024, a 12.9% increase
Quipt faced challenges including the expiration of the Medicare 75/25 blended rate and the impact of the Change Healthcare cyber-attack. Despite these, the company maintains a strong balance sheet with a Net Debt to Adjusted EBITDA Leverage Ratio of 1.5x.
Quipt Home Medical Corp. (NASDAQ: QIPT) (TSX: QIPT), a U.S. based home medical equipment provider specializing in end-to-end respiratory care, has announced it will release its fiscal third quarter 2024 financial results on August 14, 2024, after market close. The company will host a conference call for investors on August 15, 2024, at 10:00 a.m. ET.
CEO Gregory Crawford and CFO Hardik Mehta will lead the call. Participants can join using the following numbers: Canada/US Toll Free: 1 (844) 763 8274, International: 1 (647) 484 8814. A live webcast will also be available on the company's investor relations website.
Quipt Home Medical (NASDAQ: QIPT; TSX: QIPT) announced its Q2 fiscal 2024 results, reporting a 10% increase in revenue to $64.0 million and a 14% increase in adjusted EBITDA to $14.9 million. Despite the expiration of the Medicare 75/25 blended rate and withdrawal of some Medicare Advantage members, the company maintained a strong adjusted EBITDA margin of 23.3%. Net income was a loss of $1.4 million, or $0.03 per diluted share. Cash flow from operations grew to $17.1 million for the six months ended March 31, 2024. Operational highlights include an 8% increase in unique patients served and a 6% increase in unique set-ups/deliveries. The company also announced a Normal Course Issuer Bid (NCIB) for share repurchases worth up to $5.0 million. Management highlighted resilience amid industry challenges and a strong balance sheet with $32.9 million in liquidity.
Quipt Home Medical Corp. (QIPT) announced the filing of its final base shelf prospectus, allowing the company to offer up to C$300,000,000 of common shares, preferred shares, debt securities, warrants, subscription receipts, and units over a 25-month period. The prospectus aims to provide access to new capital and securities for strategic acquisitions as needed.
Quipt Home Medical Corp. will release its fiscal second-quarter 2024 financial results on May 15, 2024. The Company, a U.S.-based home medical equipment provider specializing in respiratory care, will host a conference call the following day. The call-in details are provided for investors, and a webcast link will be available on the company's website.